Skip to content

Effect of Bilateral Rhomboid Intercostal Block on Postoperative Pain After Breast Implant Surgery

The Effect of Bilateral Rhomboid Intercostal Block on Postoperative Analgesia and Opioid Consumption in Patients Undergoing Bilateral Breast Implant Surgery: A Prospective Controlled Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07448246
Acronym
RIB-BREAST
Enrollment
40
Registered
2026-03-04
Start date
2026-02-15
Completion date
2027-04-15
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Augmentation, Breast Prosthesis; Pain, Postoperative Pain

Keywords

Rhomboid Intercostal Block, RIB Block, Regional Anesthesia, Postoperative Analgesia, Breast Surgery, Tramadol PCA, Ultrasound-Guided Block

Brief summary

This prospective, randomized, single-center, study aims to evaluate the postoperative analgesic effectiveness of bilateral Rhomboid Intercostal Block (RIB) in patients undergoing elective bilateral breast prosthesis surgery. Effective postoperative pain management is essential to improve patient comfort and reduce opioid consumption. Eligible patients aged 18-65 years with ASA physical status I-II will be randomly assigned to either receive ultrasound-guided bilateral RIB block in addition to standard general anesthesia or undergo surgery without any regional block (control group). All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) with intravenous tramadol. The primary outcome of the study is total tramadol consumption within the first 24 postoperative hours. Secondary outcomes include postoperative pain scores at predefined time points, time to first analgesic requirement, need for rescue analgesia, incidence of nausea and vomiting, and block-related complications. The results of this study will help determine whether bilateral RIB block provides superior postoperative pain control compared to standard analgesic management alone in bilateral breast prosthesis surgery.

Detailed description

This prospective, randomized, single-center, single-blind clinical study is designed to evaluate the postoperative analgesic efficacy of bilateral Rhomboid Intercostal Block (RIB) in patients undergoing elective bilateral breast prosthesis surgery. Patients aged 18-65 years with American Society of Anesthesiologists (ASA) physical status I-II who are scheduled for elective bilateral breast prosthesis surgery will be screened for eligibility. After obtaining written informed consent, participants will be randomly allocated into two groups using a computer-generated randomization sequence. Group RIB: Patients will receive ultrasound-guided bilateral Rhomboid Intercostal Block in addition to standardized general anesthesia. Control Group: Patients will undergo surgery under standardized general anesthesia without any regional block intervention. The RIB procedure will be performed under aseptic conditions using ultrasound guidance. For each side, a total volume of 30 mL local anesthetic solution will be administered. The solution will consist of 5 mL of 2% lidocaine, 10 mL of 0.25% bupivacaine, and 15 mL of 0.9% sodium chloride, ensuring that maximum safe dosage limits are not exceeded. All patients will receive a standardized general anesthesia protocol. Postoperative analgesia will be provided using intravenous tramadol via patient-controlled analgesia (PCA). Tramadol dosing will be calculated according to body weight, with a reference dose of 0.1 mg/kg. The PCA bolus dose will be set at one-quarter of this reference dose, and the hourly maximum limit will be set at twelve times the bolus dose. Postoperative assessments will be conducted at 0, 1, 2, 6, 12, and 24 hours. Pain intensity will be measured using a validated Visual Analog Scale (VAS) or Numeric Rating Scale (NRS). Rescue analgesia will be administered when pain scores are ≥4, and additional analgesic consumption will be recorded. The primary endpoint is total tramadol consumption within the first 24 postoperative hours. Secondary endpoints include pain scores at predefined time points, time to first analgesic requirement, need for rescue analgesia, incidence of postoperative nausea and vomiting, analgesia-related adverse effects, and block-related complications. Data will be analyzed using appropriate statistical methods. The study will be conducted in accordance with ethical principles and will commence after approval from the institutional ethics committee.

Interventions

Ultrasound-guided bilateral rhomboid intercostal plane block performed preoperatively under aseptic conditions while patients are awake. A total of 30 mL local anesthetic solution per side will be injected between the rhomboid major muscle and the intercostal muscles at the medial border of the scapula around the 5th intercostal level. The local anesthetic mixture will consist of lidocaine and bupivacaine diluted with normal saline, ensuring that maximum safe dosage limits are not exceeded

Sponsors

Aydin Adnan Menderes University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Female patients aged 18-65 years * American Society of Anesthesiologists (ASA) physical status I-II * Scheduled for elective bilateral breast prosthesis surgery * Ability to understand the study protocol and provide written informed consent

Exclusion criteria

* Refusal to participate * Known allergy or hypersensitivity to local anesthetics (lidocaine or bupivacaine) or tramadol * Coagulation disorders or current anticoagulant therapy * Infection at the injection site * Chronic opioid use or chronic pain syndromes * Severe hepatic, renal, or cardiac disease * Neurological or psychiatric conditions interfering with pain assessment * Body mass index (BMI) \> 35 kg/m² * Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Total Tramadol Consumption Within the First 24 Hours Postoperatively0 to 24 hours postoperativelyTotal amount of tramadol (mg) administered via patient-controlled analgesia (PCA) during the first 24 postoperative hours.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026